Going a step beyond, CD19 CAR-NK cells have been engineered to express IL-15/IL-15 receptor α (IL-15/IL-15Rα) fusion protein, endowing them with enhanced persistence regarding their IL-15 secreting counterpart and potentially sustaining tumor control (101). The gene discussed is CD19; the disease is neoplasm.